Sichenzia Ross Ference LLP Represents Sunshine Biopharma Inc. in $8 Million Underwritten Public Offering
Press Release – New York, NY – February 17, 2022 – Sichenzia Ross Ference LLP today announced that it represented Sunshine Biopharma, Inc. (NASDAQ: SBFM), a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs, in an underwritten public offering. The offering consisted of 1,882,353 units at a price to the public of $4.25 per unit. Each unit consists of one share of common stock and two warrants. The gross proceeds of the offering to the company were approximately $8 million.
Aegis Capital Corp. acted as the sole book-running manager for the offering.
The shares were issued pursuant to a Form S-1 registration statement (No. 333-259394) filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on February 14, 2022. The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Jay Yamamoto and Jeff Cahlon.
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp.in $1.7 Million At-The-Market Offering Facility with SciSparc Ltd. - May 24, 2023
- Sichenzia Ross Ference LLP Represents Sunshine Biopharma, Inc. in $5.0 Million Private Placement Priced At-the-Market - May 16, 2023
- Sichenzia Ross Ference LLP Represents Lexaria Bioscience Corp. in $2.0 Million Public Offering - May 15, 2023